Our data indicate that treatment of mice with FcγRIIB mAbs prior to immunization significantly boosts humoral immune responses to model antigens as well as potentiating anti-tumour immunity, similar to FcγRII KO mice. This evidence concerns the gene FCGR2B and neoplasm.